Inozyme Pharma, Inc. (INZY)
| Market Cap | 467.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 18.10M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $20.21 |
| Previous Close | $20.00 |
| Change ($) | 0.21 |
| Change (%) | 1.05% |
| Day's Open | 20.31 |
| Day's Range | 19.90 - 21.85 |
| Day's Volume | 29,853 |
| 52-Week Range | 16.10 - 31.65 |
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of ab...
– U.S. Food and Drug Administration cleared Investigational New Drug Application –
– Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency –
Dr. Johnson Brings More Than 25 Years of Experience in Developing and Implementing Global Regulatory and Clinical Development Strategies from Preclinical Through Product Approval Dr. Johnson B...
– Dr. Sabbagh Brings More Than 20 Years of Experience in Rare Genetic Disorders and Mineral Metabolism Research Development Programs –
Upsized IPO in July 2020 raised $128.8 million in gross proceeds
About INZY
Inozyme Pharma, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is... [Read more...]
| Industry Biotechnology | IPO Date Jul 24, 2020 |
| CEO Axel Bolte | |
| Stock Exchange NASDAQ | Ticker Symbol INZY |
Analyst Forecasts
According to 4 analysts, the average rating for Inozyme Pharma stock is "Strong Buy." The 12-month stock price forecast is 36.67, which is an increase of 81.44% from the latest price.